Anixa Biosciences (ANIX) Short term Debt (2014 - 2017)
Anixa Biosciences' (ANIX) quarterly Short term Debt came in at $2.0 million in Q3 2017, down 33.33% quarter-over-quarter from $3.0 million in Q2 2017.
Powered by 
Analysis
Anixa Biosciences (ANIX) Short term Debt (2014 - 2017) Analysis & Trends
Anixa Biosciences (ANIX) has reported Short term Debt for 2 consecutive years, with $2.0 million the latest figure, recorded in Q3 2017.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Krystal Biotech | 10.21 Bn | 9.36 Bn | 112.79 Mn |
| 2 | CRISPR Therapeutics AG | 5.04 Bn | 5.04 Bn | - |
| 3 | Iovance Biotherapeutics | 3.64 Bn | 3.35 Bn | 55.72 Mn |
| 4 | Legend Biotech | 3.54 Bn | 2.58 Bn | 251.50 Mn |
| 5 | uniQure | 2.98 Bn | 2.98 Bn | 5.49 Mn |
| 6 | Beam Therapeutics | 2.52 Bn | 2.52 Bn | - |
| 7 | Precigen | 2.38 Bn | 2.38 Bn | 52.17 Mn |
| 8 | Sarepta Therapeutics | 2.15 Bn | 1.35 Bn | 251.87 Mn |
| 9 | Vericel | 1.93 Bn | 1.77 Bn | 56.40 Mn |
| 10 | Anixa Biosciences | 92.72 Mn | 92.72 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jul 31, 2017 | 2.00 Mn |
| Apr 30, 2017 | 3.00 Mn |
| Jan 31, 2017 | 3.00 Mn |
| Jan 31, 2014 | 667,956.00 |